Pharmacodynamic effects of amoxicillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumococcal strains: A phase I study

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1389-1391

  Aguilar, L ^a   Rosendo, J ^b   Balcabao, I P ^c   Martin M ^c   Gimenez M J ^a   Frias J ^b   Prieto, J ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c SCHOOL OF MEDICINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; HUMAN EXPERIMENT; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY; STREPTOCOCCUS PNEUMONIAE;

EID: 0030906719     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1389     Document Type: Article

References (16)

1. Altman, D. G. 1991. Practical statistics for medical research, p. 179-228. Chapman and Hall, London, United Kingdom.
2. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
3. Ausina, V., P. Coll, M. Sambeat, I. Puig, M. J. Condom, M. Luquin, F. Ballester, and G. Prats. 1988. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 7:343-347.
4. Balcabao, I. P., L. Aguilar, M. Martín, Y. García, R. Dal-Ré, and J. Prieto. 1996. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Antimicrob. Agents Chemother. 40:2904-2906.
5. Barriere, S. L., D. C. Ozasa, and J. Mordenti. 1985. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects. Antimicrob. Agents Chemother. 28:55-57.
6. Friedland, I. R., and H. McCraeken. 1994. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N. Engl. J. Med. 331:377-382.
7. Klastersky, J. 1983. The bactericidal activity in serum and its prognostic clinical value. Infection 11(Suppl. 2):S93-S96.
8. Klastersky, J., D. Daneau, G. Swings, and D. Weerts. 1974. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J. Infect. Dis. 129:187-193.
9. Kowalsky, S. F., R. M. Echols, and E. M. McCormick. 1990. Comparative serum bactericidal activity of ceftizoxime/metronidazole, ceftizoxime, clindamycin, and imipenem against obligate anaerobic bacteria. J. Antimicrob. Chemother. 25:767-775.
10. National Committee for Clinical Laboratory Standards. 1994. Performance standards for antimicrobial susceptibility testing - fifth international supplement. Document no. M-100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Pallarés, R., J. Liñares, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martín, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J, Med. 333:474-480.
12. Soriano, F., C. Ponte, E. Nieto, and A. Parra. 1996. Correlation of in vitro activity and pharmacokinetic parameters with in vivo effect of amoxicillin, co-amoxiclav and cefotaxime in an experimental pneumonia with Streptococcus pneumoniae in mice. J. Antimicrob. Chemother. 38:227-236.
13. Stratton, C. W., M. P. Weinstein, and L. B. Reller. 1982. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. J. Infect. Dis. 145:160-168.
14. Trautmann, M., M. Ruhnke, K. Borner, J. Wagner, and P. Koeppe. 1996. Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob. Agents Chemother. 40:776-779.
15. Wolfson, J. S., and M. N. Swartz. 1985. Serum bactericidal activity as a monitor of antibiotic therapy. N. Engl. J, Med. 312:968-975.
16. Zeiler, M. J., D. Beerman, W. Wingender, D. Föster, and P. Schaht. 1988. Bactericidal activity of ciprofloxacin, norfloxacin, and ofloxacin in serum and urine after oral administration to healthy volunteers. Infection 16(Suppl. 1):S19-S23.